Neuroblastoma

Neuroblastoma

 

Neuroblastoma is a common childhood neoplasm and is the most common extracranial solid tumor in children

Epidemiology

  • Prevalence – 600 new tumors yearly in the U.S.
  • Age – median is 2 years
  • Sex – slightly higher female predominance
  • Occurrence - mostly sporadic, 1-2% are familial

Risk Factors 

  • Neurofibromatosis
  • Nesidioblastosis
  • Hirschsprung disease

Pathophysiology

  • Malignant tumor consisting of poorly differentiated ectodermal cells derived from the neural crest

Clinical Presentation

  • Determined by tumor location and stage
  • Localized tumors are often asymptomatic (25-40% of patients)
  • Metastatic tumors frequently associated with fever, bone pain and weight loss
    • Orbital metastases – ecchymoses called raccoon eyes
    • Paraspinal disease – paresis and cord compression
    • Cervical, apical thoracic disease – Horner syndrome
  • Paraneoplastic syndromes
    • Opsoclonus-myoclonus syndrome (dancing eyes, dancing feet)
      • Involuntary eye fluttering
      • Muscle jerking
      • Ataxia
    • Vasoactive intestinal polypeptide – refractory diarrhea, failure to thrive

Diagnosis

  • Laboratory testing
    • Increased urinary vanillylmandelic acid and homovanillic acid
    • Characteristic histology on tissue specimens
    • Use criteria of International Neuroblastoma Staging System (INSS)
  • Staging
    • Bone marrow biopsy
    • CT scan
    • Metaiodobenzylguanidine scan (MIBG)

Disease Monitoring  

  • Markers
    • N-myc amplification – amplification associated with poor prognosis
    • DNA index – aneuploidy associated with poor prognosis
    • Others – not used in initial risk staging
      • Neuron specific enolase
      • Ferritin
      • Chromosome additions/deletions – 17a, 1p36
      • TrKA and B
    • Screening the general population is not recommended
Risk Group Classification
Risk Group INSS Age N-myc DNA index Shimada histopathology
Low 1
2A, 2B
2A, 2B
2A, 2B
4S
Any
<1
≥1
≥1
<1
Any
Any
Nonamplified
Amplified
Nonamplified
Any
Any
Any
Any
>1.0
Any
Any
Any
Favorable
Favorable
Intermediate 3
3
4
4S
4S
<1
≥1
<1
<1
<1
Nonamplified
Nonamplified
Nonamplified
Nonamplified
Nonamplified
Any
Any
Any
1.0
Any
Any
Favorable
Any
Favorable
Unfavorable
High 2A, 2B
3
3
3
4
4
4S
≥1
<1
≥1
≥1
<1
≥1
<1
Amplified
Amplified
Nonamplified
Amplified
Amplified
Any
Amplified
Any
Any
Any
Any
Any
Any
Any
Unfavorable
Any
Unfavorable
Any
Any
Any
Any
(Adapted with permission from Weinstein, et al., 2003, 282)

Prognosis

  • Age, stage and marker related
  • Younger patients do better; spontaneous regression occurs in 10%

See Also